Royalty Pharma (RPRX) director receives 4,545 share unit award

Rhea-AI Filing Summary

Royalty Pharma plc director Elizabeth H. Weatherman received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units. The grant was made at no cash cost to her and is classified as a compensation-related acquisition, not an open-market purchase.

The restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to the company’s 2020 Independent Director Equity Incentive Plan and the award agreement. After this grant, she holds 13,103 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WEATHERMAN ELIZABETH H

Role null

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	4,545	$0.00	--

Holdings After Transaction: Class A Ordinary Shares — 13,103 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 4,545 shares Post-grant holdings: 13,103 shares Vesting schedule: 100% cliff vesting

3 metrics

RSU grant size 4,545 shares Restricted stock units granted to director

Post-grant holdings 13,103 shares Total Class A Ordinary Shares held directly after transaction

Vesting schedule 100% cliff vesting Earlier of one-year after grant or next annual shareholder meeting

Key Terms

restricted stock units, 2020 Independent Director Equity Incentive Plan, vest 100%, grant date

4 terms

restricted stock units financial

"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Independent Director Equity Incentive Plan financial

"under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan")"

vest 100% financial

"scheduled to vest 100% on the earlier of (i) the one-year anniversary"

grant date financial

"the one-year anniversary of the grant date"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEATHERMAN ELIZABETH H

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	06/05/2026		A		4,545(1)	A	$0	13,103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Elizabeth H. Weatherman	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Royalty Pharma (RPRX) report for Elizabeth H. Weatherman?

Royalty Pharma reported that director Elizabeth H. Weatherman received a grant of 4,545 restricted stock units representing Class A Ordinary Shares. The award was issued as equity compensation at no cash cost and increased her direct holdings to 13,103 shares.

Is the recent Royalty Pharma (RPRX) Form 4 a stock purchase or a grant?

The Form 4 shows a grant/award acquisition, not an open-market stock purchase. Director Elizabeth H. Weatherman received 4,545 restricted stock units under Royalty Pharma’s equity incentive plan, classified as a compensation-related award rather than a buy transaction at market prices.

How many Royalty Pharma (RPRX) shares does Elizabeth H. Weatherman hold after the grant?

Following the award, Elizabeth H. Weatherman directly holds 13,103 Class A Ordinary Shares of Royalty Pharma. This total includes the newly granted 4,545 restricted stock units, which convert into shares as they vest under the company’s independent director equity incentive plan.

What are the vesting terms of the new Royalty Pharma (RPRX) restricted stock units?

The 4,545 restricted stock units granted to Elizabeth H. Weatherman are generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to the 2020 Independent Director Equity Incentive Plan and the award agreement.

What plan governs the latest equity award reported by Royalty Pharma (RPRX)?

The award to Elizabeth H. Weatherman was granted under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan. This plan sets the terms for director equity compensation, including vesting conditions and other requirements that apply to the 4,545 restricted stock units disclosed in the Form 4.